JP2024517381A5 - - Google Patents
Info
- Publication number
- JP2024517381A5 JP2024517381A5 JP2023562257A JP2023562257A JP2024517381A5 JP 2024517381 A5 JP2024517381 A5 JP 2024517381A5 JP 2023562257 A JP2023562257 A JP 2023562257A JP 2023562257 A JP2023562257 A JP 2023562257A JP 2024517381 A5 JP2024517381 A5 JP 2024517381A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173479P | 2021-04-11 | 2021-04-11 | |
| US63/173,479 | 2021-04-11 | ||
| US202263300567P | 2022-01-18 | 2022-01-18 | |
| US63/300,567 | 2022-01-18 | ||
| PCT/CN2022/086143 WO2022218264A1 (en) | 2021-04-11 | 2022-04-11 | Combination therapies for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517381A JP2024517381A (ja) | 2024-04-22 |
| JP2024517381A5 true JP2024517381A5 (enExample) | 2025-04-14 |
Family
ID=83640122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562257A Pending JP2024517381A (ja) | 2021-04-11 | 2022-04-11 | がんを治療するための併用療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240209092A1 (enExample) |
| EP (1) | EP4323001A4 (enExample) |
| JP (1) | JP2024517381A (enExample) |
| WO (1) | WO2022218264A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4583981A2 (en) * | 2022-09-09 | 2025-07-16 | Adagene Pte. Ltd. | Activatable anti-ctla4 antibodies for treating cancer |
| WO2024216179A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Methods for treating cancer using activatable anti-ctla4 antibody in combination with pembrolizumab |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200005662A (ko) * | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| WO2019036855A1 (en) * | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| CA3122773A1 (en) * | 2018-12-26 | 2020-07-02 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
-
2022
- 2022-04-11 JP JP2023562257A patent/JP2024517381A/ja active Pending
- 2022-04-11 EP EP22787490.6A patent/EP4323001A4/en active Pending
- 2022-04-11 US US18/554,870 patent/US20240209092A1/en active Pending
- 2022-04-11 WO PCT/CN2022/086143 patent/WO2022218264A1/en not_active Ceased